16th Apr 2007 08:05
Sinclair Pharma PLC16 April 2007 Sinclair Pharma PLC ("Sinclair" or the "Company") Admission to the Official List 16 April 2007, Sinclair plc, (AIM: SPH), is pleased to announce that admissionto the Official List of the UKLA (the "Official List") of 93.36m ordinary shares("Ordinary Shares") has occurred ("Admission") and that trading in its OrdinaryShares became effective from 8.00 a.m. today. Copies of the Prospectus dated 12 April 2007, published in connection with theAdmission has been submitted to the UK Listing Authority ("UKLA") and areavailable for inspection at the UKLA's document viewing facility, which issituated at: Financial Services Authority 25 The North Colonnade Canary Wharf London E14 5HS Copies of the Prospectus are also available for one month from the Company'sregistered office or at http://www.sinclairpharma.com/investors.php. -ends- For further information please contact: Sinclair Pharma plc Tel: +44 (0) 1483 410 600Dr Michael Flynn, CEOJerry Randall, CFOZoe McDougall, Director of Communications Piper Jaffray Tel: +44 (0) 20 3142 8700David RasoulyWill Carnwath Capital MS&L Tel +44 (0)20 7307 5340Mary Clark, Halina Kukula Notes to Editors: Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. Ithas a growing sales and marketing operation that is already present in France,Italy, UK, Spain and Portugal, and a complementary marketing partner networkthat spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractiveand undervalued products, registering these products and bringing them to marketwithin a short time frame. The company focuses on niche therapeutic areas andits current portfolio includes products for dermatological conditions and oralhealth. Other languages For versions of this press release in French, German or Japanese please [email protected] "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma